Holen Sie sich die Stockscreener-App
310.11
0.09%
-0.27
Handel nachbörslich:
316.31
6.20
+2.00%
Schlusskurs vom Vortag:
$310.38
Offen:
$318.76
24-Stunden-Volumen:
292.94K
Relative Volume:
0.60
Marktkapitalisierung:
$8.64B
Einnahmen:
$7.46M
Nettoeinkommen (Verlust:
$-303.27M
KGV:
-23.03
EPS:
-13.4668
Netto-Cashflow:
$-249.12M
1W Leistung:
+12.18%
1M Leistung:
-0.19%
6M Leistung:
+508.30%
1J Leistung:
+849.80%
1-Tages-Spanne:
$306.36
$323.69
1-Wochen-Bereich:
$279.27
$338.31
52-Wochen-Spanne:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
310.11 | 8.64B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com
BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial - Benzinga
Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy - TradingView
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - manilatimes.net
In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
(PRAX) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history - Yahoo Finance UK
Praxis Precision Medicines announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
18 new Praxis hires receive stock awards that vest over 4 years - Stock Titan
PRAX SEC FilingsPraxis Precision Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 13.4%Time to Buy? - MarketBeat
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $525 - Moomoo
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? - MSN
FDA Prioritizes Review of Praxis Precision's (PRAX) Drug Applica - gurufocus.com
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine - marketscreener.com
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - Bitget
FDA fast-tracks Praxis drug for rare childhood epilepsy disorders - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Truist Financial - MarketBeat
(PRAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com
Aug Swings: Is Praxis Precision Medicines Inc forming bullish engulfing patterns2026 Reactions & Reliable Momentum Entry Alerts - baoquankhu1.vn
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - AOL.com
5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 FilingNews and Statistics - IndexBox
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - AOL.com
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? - Yahoo Finance
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Insider Monkey
PRAX PE Ratio & Valuation, Is PRAX Overvalued - Intellectia AI
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - AOL.com
Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Cormorant Sells $9.31M in Praxis Shares, Holding Remains Top Position | 2026 UpdateNews and Statistics - IndexBox
This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter. - Bitget
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA FilingsHas The Bull Case Changed? - simplywall.st
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):